These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 16804830

  • 21. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.
    Astermark J, Oldenburg J, Escobar M, White GC, Berntorp E, Malmö International Brother Study study group.
    Haematologica; 2005 Jul; 90(7):924-31. PubMed ID: 15996930
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Risk factors for inhibitor development in hemophilia A.
    Oldenburg J, Brackmann HH, Schwaab R.
    Haematologica; 2000 Oct; 85(10 Suppl):7-13; discussion 13-4. PubMed ID: 11187876
    [Abstract] [Full Text] [Related]

  • 24. Inhibitors in haemophilia: pathophysiology.
    Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J.
    Haemophilia; 2004 Oct; 10 Suppl 4():146-51. PubMed ID: 15479388
    [Abstract] [Full Text] [Related]

  • 25. Inhibitor development: patient-determined risk factors.
    Astermark J.
    Haemophilia; 2010 May; 16(102):66-70. PubMed ID: 19298384
    [Abstract] [Full Text] [Related]

  • 26. Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population.
    Boekhorst J, Verbruggen B, Lavergne JM, Costa JM, Schoormans SC, Brons PP, van Kraaij MG, Nováková IR, van Heerde WL.
    Br J Haematol; 2005 Oct; 131(1):109-17. PubMed ID: 16173970
    [Abstract] [Full Text] [Related]

  • 27. Inhibitor development.
    Astermark J, Lacroix-Desmazes S, Reding MT.
    Haemophilia; 2008 Jul; 14 Suppl 3():36-42. PubMed ID: 18510520
    [Abstract] [Full Text] [Related]

  • 28. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.
    Boekhorst J, Lari GR, D'Oiron R, Costa JM, Nováková IR, Ala FA, Lavergne JM, VAN Heerde WL.
    Haemophilia; 2008 Jul; 14(4):729-35. PubMed ID: 18503540
    [Abstract] [Full Text] [Related]

  • 29. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R.
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [Abstract] [Full Text] [Related]

  • 30. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development.
    Goodeve AC, Peake IR.
    Semin Thromb Hemost; 2003 Feb; 29(1):23-30. PubMed ID: 12640561
    [Abstract] [Full Text] [Related]

  • 31. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 32. Haemophilia A: mutation type determines risk of inhibitor formation.
    Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J.
    Thromb Haemost; 1995 Dec; 74(6):1402-6. PubMed ID: 8772209
    [Abstract] [Full Text] [Related]

  • 33. Immune response to FVIII in hemophilia A: an overview of risk factors.
    Ghosh K, Shetty S.
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
    [Abstract] [Full Text] [Related]

  • 34. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
    von Auer Ch, Oldenburg J, von Depka M, Escuriola-Ettinghausen C, Kurnik K, Lenk H, Scharrer I.
    Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
    [Abstract] [Full Text] [Related]

  • 35. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM, RITS-FITNHES Study Group.
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [Abstract] [Full Text] [Related]

  • 36. Prevention and prediction of inhibitor risk.
    Astermark J.
    Haemophilia; 2012 Jul; 18 Suppl 4():38-42. PubMed ID: 22726081
    [Abstract] [Full Text] [Related]

  • 37. New associations: INFG and TGFB1 genes and the inhibitor development in severe haemophilia A.
    de Alencar JB, Macedo LC, de Barros MF, Rodrigues C, Shinzato AH, Pelissari CB, Machado J, Sell AM, Visentainer JE.
    Haemophilia; 2015 Jul; 21(4):e312-6. PubMed ID: 25930091
    [Abstract] [Full Text] [Related]

  • 38. [Screening and analysis of coagulation factor VIII inhibitor in patients with hemophilia A].
    Zhang AL, Yang LH, Liu XE, Zhao H, Zhang JH, Dong CX, Qi XL, Qin XY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):968-70. PubMed ID: 21867625
    [Abstract] [Full Text] [Related]

  • 39. The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran.
    Haghpanah S, Sahraiian M, Afrasiabi A, Enayati S, Peyvandi F, Karimi M.
    Haemophilia; 2011 Sep; 17(5):820-1. PubMed ID: 21371201
    [No Abstract] [Full Text] [Related]

  • 40. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
    Mancuso ME, Graca L, Auerswald G, Santagostino E.
    Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.